Elevance Health Signals Margin Recovery with 2027 EPS Growth Target

What happened

Elevance Health announced at a UBS conference that it expects adjusted EPS to grow at least 12% in 2027 from a raised 2026 baseline of at least $26.75, signaling management's confidence in margin recovery. This follows a challenging period marked by CMS sanctions on Medicare Advantage enrollment and elevated medical costs that had pressured the benefit expense ratio in 2025 and early 2026. The raised 2026 EPS guidance (from at least $25.50 to $26.75) suggests that the company has navigated the regulatory and cost headwinds better than previously anticipated. The 12% growth target for 2027 implies adjusted EPS of around $30.00, which would represent a significant reacceleration from the flat-to-down earnings trend seen in recent quarters. However, investors should treat conference commentary with caution, as it is not a formal guidance update and the company has not yet demonstrated sustained improvement in its benefit expense ratio or resolution of all regulatory issues.

Implication

The raised 2026 baseline and 2027 growth target suggest that management believes the worst of the CMS sanctions and medical cost spikes are behind them, which could remove a key overhang on the stock. If the company delivers on the 12% growth, the forward P/E would compress to around 10.5x at current prices (assuming no change), which is attractive relative to historical averages. However, the market may have already priced in this recovery, with the stock likely having risen from the $316 level noted in April to a higher price by November, so margin of safety may have narrowed. Investors should monitor quarterly medical loss ratios and any updates on CMS enforcement status to validate the margin recovery, as any setback could reverse recent gains and lead to a re-rating downward. Given the improved outlook, the investment thesis shifts from a cautious WAIT to a more constructive stance, but entry timing should be disciplined, waiting for pullbacks or confirmation of earnings delivery.

Thesis delta

The previous thesis hinged on removal of CMS sanctions and stabilization of the benefit expense ratio before a more constructive stance. The raised 2026 EPS baseline and 12% growth target for 2027 indicate management expects those obstacles to clear, shifting the investment case from cautious to increasingly positive. While not yet a full-throated buy, the evidence argues for upgrading the rating bias to buy-on-dips pending confirmation of margin trends.